99 related articles for article (PubMed ID: 24370033)
1. [Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
Qu S; Liao LS; Wei TN; Lin Y; Chen BY; Chen WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1482-5. PubMed ID: 24370033
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
[TBL] [Abstract][Full Text] [Related]
3. [Effect of different regimens on bone disease of multiple myeloma].
Bao L; Lu XJ; Zhang XH; Lai YY; Zhu HH; Lu J; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):221-5. PubMed ID: 21569702
[TBL] [Abstract][Full Text] [Related]
4. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
6. [Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
Bao L; Huang XJ
Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):243-7. PubMed ID: 21600091
[TBL] [Abstract][Full Text] [Related]
7. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
9. [The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].
Zhang X; Chang CK; Wu LY; Zhang Z; Zhou LY; Xiao C; Li X
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):660-3. PubMed ID: 22339822
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
[TBL] [Abstract][Full Text] [Related]
12. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
Li CM; Lu H; Wu HX; Qiu HX; Qian SX; Xu W; Li JY; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1511-4. PubMed ID: 21176361
[TBL] [Abstract][Full Text] [Related]
14. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
[TBL] [Abstract][Full Text] [Related]
15. [The clinical study on treatment with bortezomib for multiple myeloma].
Chen C; Zhao CL; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):265-7. PubMed ID: 21569711
[No Abstract] [Full Text] [Related]
16. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
17. [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Zhong YP; Chen SL; Li X; Hu Y; Zhang JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):214-7. PubMed ID: 19236782
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096
[TBL] [Abstract][Full Text] [Related]
20. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]